0001062993-24-012414.txt : 20240611
0001062993-24-012414.hdr.sgml : 20240611
20240611184754
ACCESSION NUMBER: 0001062993-24-012414
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240607
FILED AS OF DATE: 20240611
DATE AS OF CHANGE: 20240611
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Wallace Peggy
CENTRAL INDEX KEY: 0001876466
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40886
FILM NUMBER: 241037091
MAIL ADDRESS:
STREET 1: C/O COGNITION THERAPEUTICS, INC.
STREET 2: 2500 WESTCHESTER AVE.
CITY: PURCHASE
STATE: NY
ZIP: 10577
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: COGNITION THERAPEUTICS INC
CENTRAL INDEX KEY: 0001455365
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2403 SIDNEY STREET
STREET 2: SUITE 261
CITY: PITTSBURGH
STATE: PA
ZIP: 15203
BUSINESS PHONE: 412-481-2210
MAIL ADDRESS:
STREET 1: 2500 WESTCHESTER AVE
CITY: PURCHASE
STATE: NY
ZIP: 10577
FORMER COMPANY:
FORMER CONFORMED NAME: COGNITION THERAPUTICS INC
DATE OF NAME CHANGE: 20090204
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0508
4
2024-06-07
0001455365
COGNITION THERAPEUTICS INC
CGTX
0001876466
Wallace Peggy
C/O COGNITION THERAPEUTICS, INC.
2500 WESTCHESTER AVE
PURCHASE
NY
10577
1
0
0
0
0
Common Stock
2024-06-07
4
A
0
8500
0.00
A
52461
D
Stock Option (right to buy)
1.95
2024-06-07
4
A
0
8500
0.00
A
2034-06-07
Common Stock
8500
8500
D
Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on the earlier of (i) June 7, 2025 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
The option vests in full on the earlier of (i) June 7, 2025 or (ii) on the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service as a director as of the applicable vesting date.
/s/ John Brendan Doyle, Attorney-in-Fact
2024-06-11